ReviewTranslational gastroenterology and hepatology2016
Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation.
Review in Translational gastroenterology and hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- The Role of TARE for Bridging and Downstaging of HCC Before Resection or Liver Transplant.Cancers · 2026Article
- A Machine Learning Guided System for Therapeutic Decision-Making in Intra-Arterial Therapy of Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Recent Advances in Liver Transplantation for Hepatocellular Carcinoma.Current treatment options in oncology · 2024Review
- Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia.Journal of hepatocellular carcinoma · 2024Article
- Review
- Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation.World journal of transplantation · 2022Review
- Neoadjuvant treatment strategies for hepatocellular carcinoma.World journal of gastrointestinal surgery · 2021Review
- Transplant Oncology: An Evolving Field in Cancer Care.Cancers · 2021Review
- Milan-out Criteria and Worse Intention-to-Treat Outcome Postliver Transplantation.Transplantation direct · 2019Article
- Association between Ambient Particulate Matter 2.5 Exposure and Mortality in Patients with Hepatocellular Carcinoma.International journal of environmental research and public health · 2019Article
- Validated model for prediction of recurrent hepatocellular carcinoma after liver transplantation in Asian population.World journal of gastrointestinal oncology · 2019Article
- Nomogram predicting extrahepatic metastasis of hepatocellular carcinoma based on commonly available clinical data.JGH open : an open access journal of gastroenterology and hepatology · 2019Article
- Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong.Journal of clinical and translational hepatology · 2018Review
- Stereotactic body radiotherapy used as a bridge to liver transplant in patients with hepatocellular carcinoma and Child-Pugh score ≥8 cirrhosis.Journal of radiosurgery and SBRT · 2018Article
- Identification of WT1 as determinant of heptatocellular carcinoma and its inhibition by Chinese herbal medicineOncotarget · 2017Article
- Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same?Translational gastroenterology and hepatology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a common primary malignancy worldwide especially in the patients with the background of chronic liver disease. Liver transplantation (LT) is the only curative treatment effective for both malignancy as well as the cirrhosis and portal hypertension. Unfortunately, living donor is not always possible and the deceased graft is scarce. Neoadjuvant therapies, therefore, have been developed as a downstaging treatment to try to downstage the tumor within the transplant criteria, or as a bridging therapy to control the tumor growth in patients while waiting in the transplant list. This paper reviewed the common modalities used as bridging and downstaging therapies for patients suffering from HCC before undergoing LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.